Antoni Ribas

Antoni Ribas is a leading authority on mechanisms of resistance to PD-1 blockade and other immunotherapies. His research identified beta-2-microglobulin loss of function mutations as a key mechanism of acquired resistance to PD-1 therapy in melanoma. He discovered JAK1 and JAK2 loss-of-function mutations enabling tumor cells to escape IFN-gamma signaling and immune killing. His laboratory continues to define genetic and epigenetic resistance pathways and co-leads major melanoma immunotherapy trials.